Antengene
Tracked across 2 events · 15 articles · First seen Jun 03, 2026 · Last active Jun 10, 2026
Live sentiment trends, attention charts, and prominence tracking available on the
NewsDesk Dashboard
Tech
Antengene Corporation Limited announced the presentation of its first preclinical data on ATG-207, an αCD3-TGF-β bifunctional fusion protein, at the 2026 European Society of Endocrinology in London, United Kingdom. ATG-207 is designed to treat T…
Impact: Antengene is presenting the first preclinical data for its drug candidate ATG-207, which could positively impact its stock price and future revenue streams if the drug progresses successfully through clinical trials.
Jun 03, 2026 · 7 articles
Tech
Antengene Corporation Limited received Investigational New Drug (IND) approval from China's China — National Medical Products Administration (NMPA) for its Phase I ATTRACT study of ATG-201. ATG-201 is a CD19/CD3 bispecific T-cell engager antibody designed…
Impact: Antengene received IND approval for ATG-201 in China, marking a significant expansion into autoimmune diseases and potentially increasing its market value and strategic importance. Antengene will conduct initial clinical trials in China and Australia before transferring development to EITC.
Jun 10, 2026 · 8 articles
100
Antengene presented preclinical dataAntengene presents ATG-207...
100
China — National Medical Products Administration approved IND application AntengeneAntengene ATG-201 IND...
90
Antengene will conduct trials ATG-201Antengene ATG-201 IND...
80
Antengene expanded strategic focusAntengene ATG-201 IND...
70
Antengene entered licensing agreement EITCAntengene presents ATG-207...
70
Antengene entered licensing agreement EITCAntengene ATG-201 IND...
NEWSDESK
Track Antengene live
Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.
Open Dashboard